You will now be redirected to the GD3 website
Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3Chemistry
Structure-Based Drug Design, Identification and Characterization
In the structure-based drug design (SBDD) approach, the 3D structure of a ligand bound to its biological target is determined with the ultimate goal to identify suitable small molecule ligands. The use of X-ray crystallography and molecular modeling can dramatically accelerate the process of optimizing early lead compounds, transforming them from leads with weak activities into highly potent, and selective, clinical candidates. Whenever possible, our team of expert chemists incorporate these technologies into our drug discovery collaborations.
Specific services include:
- Production and purification of target proteins
- X-ray crystallography of small molecule inhibitors bound to protein targets
- Molecular modeling for lead optimization
- Biophysical analysis of protein-inhibitor interactions to evaluate binding modes (thermodynamic and kinetic analysis)
Learn more about